|
시장보고서
상품코드
2152235
재사용 가능 바이오리액터 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 바이오리액터 유형별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Reusable Bioreactors Market Size, Share & Trends Analysis Report By Product (Reusable Bioreactor Systems, Reusable Bioreactor Accessories & Components), By Bioreactor Type, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
재사용 가능 바이오리액터 시장 요약
세계 재사용 가능 바이오리액터 시장 규모는 2025년에 82억 달러로 평가되며, 2026년 93억 달러에서 2033년까지 309억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지의 연평균 성장률(CAGR)은 18.7%에 달할 것으로 전망됩니다.
북미는 시장을 주도하고 있으며, 2025년에는 34.6%라는 가장 큰 매출 점유율을 차지했습니다. 이러한 성장은 전 세계적으로 비용 효율적이고 확장성이 뛰어나며 지속가능한 바이오의약품 제조 공정을 위한 재사용 가능 바이오리액터의 채택 확대에 의해 주도되고 있습니다.
제약, 생명공학, 식품, 산업용 분야에서 확장성이 높고 비용 효율이 뛰어난 바이오프로세싱에 대한 수요가 증가하고 있는 것을 배경으로, 이 업계는 눈부신 성장을 이루고 있습니다. 재사용 가능 바이오리액터는 반복적인 생산 주기와 대규모 운영에 대응할 수 있기 때문에 각 제조사들은 설비 가동률 향상과 장기적인 운영 비용 절감을 목적으로 이러한 시스템의 도입을 추진하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법 및 범위
제2장 요약
제3장 시장 : 변수, 동향, 범위
- 시장 계보 전망
- 시장 역학
- 업계 분석 도구
제4장 제품별 비즈니스 분석
- 재사용 가능 바이오리액터 시장 : 제품별 동향 분석
- 재사용 가능 바이오리액터 시스템
- 재사용 가능 바이오리액터 부속품 및 부품
- 기타
제5장 바이오리액터 유형별 비즈니스 분석
- 재사용 가능 바이오리액터 시장 : 바이오리액터 유형별 동향 분석
- 교반조형 바이오리액터
- 에어리프트형 바이오리액터
- 기포탑형 바이오리액터
- 충진층형 바이오리액터
- 기타
제6장 용도별 비즈니스 분석
- 재사용 가능 바이오리액터 시장 : 용도별 동향 분석
- 단일클론 항체
- 백신
- 재조합 단백질
- 세포·유전자 치료
- 미생물 유래 제품
- 기타
제7장 최종 용도별 비즈니스 분석
- 재사용 가능 바이오리액터 시장 : 최종 용도별 분석
- 제약 및 바이오의약품 기업
- CRO·CDMO
- 학술·연구 기관
- 기타
제8장 지역별 비즈니스 분석
- 재사용 가능 바이오리액터 시장 점유율 : 지역별, 2025년·2033년
- 북미
- 북미 재사용 가능 바이오리액터 시장, 2021-2033년
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽 재사용 가능 바이오리액터 시장, 2021-2033년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 아시아태평양의 재사용 가능 바이오리액터 시장, 2021-2033년
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 라틴아메리카의 재사용 가능 바이오리액터 시장, 2021-2033년
- 브라질
- 아르헨티나
- 중동 및 아프리카
- MEA 재사용 가능 바이오리액터 시장, 2021-2033년
- 남아프리카
- 사우디아라비아
- UAE
- 쿠웨이트
제9장 경쟁 현황
- 기업 분류
- 기업 점유율 및 포지셔닝 분석, 2025년
- 전략 매핑
- 기업 개요 및 목록
- Eppendorf SE
- Pierre Guerin(a subsidiary of Equans)
- GEA Group
- ZETA
- ABEC, Inc.
- Infors AG
- Solaris Biotech
- bbi-biotech
- Getinge AB
- Actini Group
Reusable Bioreactors Market Summary
The global reusable bioreactors market size was valued at USD 8.2 billion in 2025 and is projected to grow from USD 9.3 billion in 2026 to USD 30.9 billion by 2033, at a CAGR of 18.7% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 34.6% in 2025. The growth is driven by the rising adoption of reusable bioreactors for cost-effective, scalable, and sustainable biopharmaceutical manufacturing processes globally.
The industry is witnessing significant growth, driven by increasing demand for scalable and cost-efficient bioprocessing across pharmaceutical, biotechnology, food, and industrial applications. The ability of reusable bioreactors to support repeated production cycles and large-scale operations is encouraging manufacturers to adopt these systems for greater equipment utilization and lower long-term operating costs.
Global Reusable Bioreactors Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global reusable bioreactors market report on the basis of product, bioreactor type, application, end use, and region:
- Product Outlook (Revenue, USD Billion, 2021 - 2033)
- Reusable Bioreactor Systems
- Up to 10 L
- 11-100 L
- 101-500 L
- 501-1,500 L
- Above 1,500 L
- Reusable Bioreactor Accessories & Components
- Others
- Bioreactor Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Stirred-tank Bioreactors
- Air-lift Bioreactors
- Bubble-column Bioreactors
- Packed-bed Bioreactors
- Other Bioreactors
- Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Cell & Gene Therapies
- Microbial Products
- Other Applications
- End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Pharmaceutical & Biopharmaceutical Companies
- CROs & CDMOs
- Academic & Research Institutes
- Other End Users
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Product Segment
- 1.1.1.2. Bioreactor Type Segment
- 1.1.1.3. Application Segment
- 1.1.1.4. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. List of Secondary Sources
- 1.9.3. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing Adoption of Cost-Effective Reusable Bioreactors
- 3.2.1.2. Increasing Demand for Large-Scale Biologics Manufacturing
- 3.2.1.3. Growing Focus on Sustainable and Waste-Reducing Bioprocessing
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Higher Cleaning, Sterilization, and Cross-Contamination Risks
- 3.2.2.2. High Initial Capital Investment and Infrastructure Requirements
- 3.2.3. Market Opportunities Analysis
- 3.2.4. Market Challenges Analysis
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Economic landscape
- 3.3.2.5. Legal landscape
- 3.3.2.6. Environmental landscape
- 3.3.1. Porter's Five Forces Analysis
Chapter 4. Product Business Analysis
- 4.1. Segment Dashboard
- 4.2. Reusable Bioreactors Market: Product Movement Analysis
- 4.3. Reusable Bioreactor Systems
- 4.3.1. Reusable Bioreactor Systems Market, 2021 - 2033 (USD Billion)
- 4.3.2. Up to 10 L
- 4.3.2.1. Up to 10 L Market, 2021 - 2033 (USD Billion)
- 4.3.3. 11-100 L
- 4.3.3.1. 11-100 L Market, 2021 - 2033 (USD Billion)
- 4.3.4. 101-500 L
- 4.3.4.1. 101-500 L Market, 2021 - 2033 (USD Billion)
- 4.3.5. 501-1,500 L
- 4.3.5.1. 501-1,500 L Market, 2021 - 2033 (USD Billion)
- 4.3.6. Above 1,500 L
- 4.3.6.1. Above 1,500 L Market, 2021 - 2033 (USD Billion)
- 4.4. Reusable Bioreactor Accessories & Components
- 4.4.1. Reusable Bioreactor Accessories & Components Market, 2021 - 2033 (USD Billion)
- 4.5. Others
- 4.5.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Bioreactor Type Business Analysis
- 5.1. Segment Dashboard
- 5.2. Reusable Bioreactors Market: Bioreactor Type Movement Analysis
- 5.3. Stirred-tank Bioreactors
- 5.3.1. Stirred-tank Bioreactors Market, 2021 - 2033 (USD Billion)
- 5.4. Air-lift Bioreactors
- 5.4.1. Air-lift Bioreactors Market, 2021 - 2033 (USD Billion)
- 5.5. Bubble-column Bioreactors
- 5.5.1. Bubble-column Bioreactors Market, 2021 - 2033 (USD Billion)
- 5.6. Packed-bed Bioreactors
- 5.6.1. Packed-bed Bioreactors Market, 2021 - 2033 (USD Billion)
- 5.7. Other Bioreactors
- 5.7.1. Other Bioreactors Market, 2021 - 2033 (USD Billion)
Chapter 6. Application Business Analysis
- 6.1. Segment Dashboard
- 6.2. Reusable Bioreactors Market: Application Movement Analysis
- 6.3. Monoclonal Antibodies
- 6.3.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Billion)
- 6.4. Vaccines
- 6.4.1. Vaccines Market, 2021 - 2033 (USD Billion)
- 6.5. Recombinant Proteins
- 6.5.1. Recombinant Proteins Market, 2021 - 2033 (USD Billion)
- 6.6. Cell & Gene Therapies
- 6.6.1. Cell & Gene Therapies Market, 2021 - 2033 (USD Billion)
- 6.7. Microbial Products
- 6.7.1. Microbial Products Market, 2021 - 2033 (USD Billion)
- 6.8. Other Applications
- 6.8.1. Other Applications Market, 2021 - 2033 (USD Billion)
Chapter 7. End Use Business Analysis
- 7.1. Segment Dashboard
- 7.2. Reusable Bioreactors Market: End Use Analysis
- 7.3. Pharmaceutical & Biopharmaceutical Companies
- 7.3.1. Pharmaceutical & Biopharmaceutical Companies Market, 2021 - 2033 (USD Billion)
- 7.4. CROs & CDMOs
- 7.4.1. CROs & CDMOs Market, 2021 - 2033 (USD Billion)
- 7.5. Academic & Research Institutes
- 7.5.1. Academic & Research Institutes Market, 2021 - 2033 (USD Billion)
- 7.6. Other End Users
- 7.6.1. Other End Users Market, 2021 - 2033 (USD Billion)
Chapter 8. Regional Business Analysis
- 8.1. Reusable Bioreactors Market Share By Region, 2025 & 2033
- 8.2. North America
- 8.2.1. North America Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.2.2. U.S.
- 8.2.2.1. Key Country Dynamics
- 8.2.2.2. Competitive Scenario
- 8.2.2.3. Regulatory Framework
- 8.2.2.4. U.S. Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.2.3. Canada
- 8.2.3.1. Key Country Dynamics
- 8.2.3.2. Competitive Scenario
- 8.2.3.3. Regulatory Framework
- 8.2.3.4. Canada Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.2.4. Mexico
- 8.2.4.1. Key Country Dynamics
- 8.2.4.2. Competitive Scenario
- 8.2.4.3. Regulatory Framework
- 8.2.4.4. Mexico Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3. Europe
- 8.3.1. Europe Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.2. UK
- 8.3.2.1. Key Country Dynamics
- 8.3.2.2. Competitive Scenario
- 8.3.2.3. Regulatory Framework
- 8.3.2.4. UK Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.3. Germany
- 8.3.3.1. Key Country Dynamics
- 8.3.3.2. Competitive Scenario
- 8.3.3.3. Regulatory Framework
- 8.3.3.4. Germany Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.4. France
- 8.3.4.1. Key Country Dynamics
- 8.3.4.2. Competitive Scenario
- 8.3.4.3. Regulatory Framework
- 8.3.4.4. France Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.5. Italy
- 8.3.5.1. Key Country Dynamics
- 8.3.5.2. Competitive Scenario
- 8.3.5.3. Regulatory Framework
- 8.3.5.4. Italy Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.6. Spain
- 8.3.6.1. Key Country Dynamics
- 8.3.6.2. Competitive Scenario
- 8.3.6.3. Regulatory Framework
- 8.3.6.4. Spain Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.7. Denmark
- 8.3.7.1. Key Country Dynamics
- 8.3.7.2. Competitive Scenario
- 8.3.7.3. Regulatory Framework
- 8.3.7.4. Denmark Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.8. Sweden
- 8.3.8.1. Key Country Dynamics
- 8.3.8.2. Competitive Scenario
- 8.3.8.3. Regulatory Framework
- 8.3.8.4. Sweden Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.3.9. Norway
- 8.3.9.1. Key Country Dynamics
- 8.3.9.2. Competitive Scenario
- 8.3.9.3. Regulatory Framework
- 8.3.9.4. Norway Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.2. Japan
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Competitive Scenario
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Japan Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.3. China
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Competitive Scenario
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. China Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.4. India
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Competitive Scenario
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. India Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.5. Australia
- 8.4.5.1. Key Country Dynamics
- 8.4.5.2. Competitive Scenario
- 8.4.5.3. Regulatory Framework
- 8.4.5.4. Australia Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.6. Thailand
- 8.4.6.1. Key Country Dynamics
- 8.4.6.2. Competitive Scenario
- 8.4.6.3. Regulatory Framework
- 8.4.6.4. Thailand Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.4.7. South Korea
- 8.4.7.1. Key Country Dynamics
- 8.4.7.2. Competitive Scenario
- 8.4.7.3. Regulatory Framework
- 8.4.7.4. South Korea Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.5. Latin America
- 8.5.1. Latin America Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.5.2. Brazil
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Competitive Scenario
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Brazil Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.5.3. Argentina
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Competitive Scenario
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Argentina Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.6. MEA
- 8.6.1. MEA Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.6.2. South Africa
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Competitive Scenario
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. South Africa Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.6.3. Saudi Arabia
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Competitive Scenario
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Saudi Arabia Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.6.4. UAE
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Competitive Scenario
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. UAE Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
- 8.6.5. Kuwait
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Competitive Scenario
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Kuwait Reusable Bioreactors Market, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Company Market Share/ Position Analysis, 2025
- 9.3. Strategy Mapping
- 9.4. Company Profiles/Listing
- 9.4.1. Eppendorf SE
- 9.4.1.1. Overview
- 9.4.1.2. Financial Performance
- 9.4.1.3. Product Benchmarking
- 9.4.1.4. Strategic Initiatives
- 9.4.2. Pierre Guerin (a subsidiary of Equans)
- 9.4.2.1. Overview
- 9.4.2.2. Financial Performance
- 9.4.2.3. Product Benchmarking
- 9.4.2.4. Strategic Initiatives
- 9.4.3. GEA Group
- 9.4.3.1. Overview
- 9.4.3.2. Financial Performance
- 9.4.3.3. Product Benchmarking
- 9.4.3.4. Strategic Initiatives
- 9.4.4. ZETA
- 9.4.4.1. Overview
- 9.4.4.2. Financial Performance
- 9.4.4.3. Product Benchmarking
- 9.4.4.4. Strategic Initiatives
- 9.4.5. ABEC, Inc.
- 9.4.5.1. Overview
- 9.4.5.2. Financial Performance
- 9.4.5.3. Product Benchmarking
- 9.4.5.4. Strategic Initiatives
- 9.4.6. Infors AG
- 9.4.6.1. Overview
- 9.4.6.2. Financial Performance
- 9.4.6.3. Product Benchmarking
- 9.4.6.4. Strategic Initiatives
- 9.4.7. Solaris Biotech
- 9.4.7.1. Overview
- 9.4.7.2. Financial Performance
- 9.4.7.3. Product Benchmarking
- 9.4.7.4. Strategic Initiatives
- 9.4.8. bbi-biotech
- 9.4.8.1. Overview
- 9.4.8.2. Financial Performance
- 9.4.8.3. Product Benchmarking
- 9.4.8.4. Strategic Initiatives
- 9.4.9. Getinge AB
- 9.4.9.1. Overview
- 9.4.9.2. Financial Performance
- 9.4.9.3. Product Benchmarking
- 9.4.9.4. Strategic Initiatives
- 9.4.10. Actini Group
- 9.4.10.1. Overview
- 9.4.10.2. Financial Performance
- 9.4.10.3. Product Benchmarking
- 9.4.10.4. Strategic Initiatives
- 9.4.1. Eppendorf SE
